Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells

Research output: Contribution to journalLetter

8 Citations (Scopus)
Original languageEnglish
Pages (from-to)855-857
Number of pages3
JournalLeukemia
Volume24
Issue number4
DOIs
Publication statusPublished - 1 Jan 2010

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this